Steroid‐Induced Mental Disorders in Oncology Patients: A 10‐Year Retrospective Case Series Review
Psycho-Oncology · 2025
DOI: 10.1002/pon.70137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psycho-Oncology, 2025. Verfasst von Niall Seymour und 6 weiteren Autor:innen. Beteiligte Einrichtung: University College Cork, Cork, Ireland. Hauptthemen laut MEDLINE: Neoplasms, Mental Disorders, Dexamethasone, Adrenal Cortex Hormones. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Patients with cancer are commonly prescribed corticosteroids for a variety of indications. Corticosteroids have long been known to affect mental state. Neuropsychiatric effects range from insomnia, cognitive impairment, and mood symptoms to psychosis and mania. In this study, we aimed to investigate the demographics, steroid exposure, referring indications, symptom profiles, and subsequent treatments of steroid‐induced mental disorders in oncology patients.
Methods
We conducted a retrospective chart review of patients diagnosed with a steroid‐induced mental disorder, as assessed by the psycho‐oncology team in Cork University Hospital from 2626 referrals to the service between January 2010 to December 2019.
Results
In total, 297 patients had a diagnosis of steroid‐induced mental disorder (11% of referrals). 60.6% were female and mean age ± standard deviation (SD) was 57.5 ± 12.9 years. Breast cancer was the most frequent malignancy among females. Haematological cancer was the most frequent among males and the second most frequent among females. The most commonly prescribed steroid was dexamethasone, followed by prednisolone. The median (interquartile range [IQR]) cumulative weekly prednisolone equivalent dose was 186 mg (125–350 mg), with a median (IQR) duration of steroid exposure before symptom onset of 14 (6–47) days. The most frequently recorded symptoms following psychiatric assessment included insomnia, anxiety, and irritability. Psychotropics were commenced in n = 174 (74%) patients, with antipsychotics prescribed to 62.1%. A watchful wait approach was adopted for 25.5% of the patients. 90.2% ( n = 185/205) of the patients experienced either complete or partial resolution of the symptoms at their first clinical review.
Conclusions
Steroid‐induced mental disorders can cause significant comorbidity in patients receiving cancer treatment. The most common symptoms recorded during assessment included insomnia, anxiety, and irritability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University College Cork, Cork, Ireland.
- Cork University Hospital, Cork, Ireland.
- St Vincent's University Hospital, Dublin, Ireland.
ORCID-Profile: Niall Seymour
Zitieren
APA
Seymour, N., Ismail, M. F., Doherty, K., Bowler, A., Bambury, R., Iqbal, S., & Cassidy, E. M. (2025). Steroid‐Induced Mental Disorders in Oncology Patients: A 10‐Year Retrospective Case Series Review. Psycho-Oncology. https://doi.org/10.1002/pon.70137
Vancouver
Seymour N, Ismail MF, Doherty K, Bowler A, Bambury R, Iqbal S, et al. Steroid‐Induced Mental Disorders in Oncology Patients: A 10‐Year Retrospective Case Series Review. Psycho-Oncology. 2025. doi:10.1002/pon.70137
BibTeX
@article{Seymour2025,
author = {Seymour, Niall and Ismail, Muhammad Fahmi and Doherty, Kieran and Bowler, Ann and Bambury, Richard and Iqbal, Shahid and Cassidy, Eugene M},
title = {Steroid‐Induced Mental Disorders in Oncology Patients: A 10‐Year Retrospective Case Series Review},
journal = {Psycho-Oncology},
year = {2025},
doi = {10.1002/pon.70137}
}
EUVIMED